# Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

> **NCT05177068** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** fruquintinib + sintilimab + SOX

## Key facts

- **NCT ID:** NCT05177068
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-13
- **Primary completion:** 2024-10-16
- **Final completion:** 2025-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05177068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05177068, "Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05177068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*